Publications
- Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia2021 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders2019 | Faculty of Medicine in Hradec Králové
- Treatment of elderly and comorbid patients with chronic lymphocytic leukemia2017 | Faculty of Medicine in Hradec Králové
- Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies2017 | Faculty of Medicine in Hradec Králové
- Primary testicular lymphoma2017 | Faculty of Medicine in Hradec Králové
- Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
- Venous thromboembolism in patients with chronic lymphocytic leukemia2015 | Faculty of Medicine in Hradec Králové
- Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia2015 | Faculty of Medicine in Hradec Králové
- Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia2014 | Faculty of Medicine in Hradec Králové
- The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab2013 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen
Loading network view...